Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

NCT04411433 is registered in ClinicalTrials.gov with Ministry of Health, Turkey as lead sponsor.

NCT NCT04411433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04411433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
Lead sponsor
Ministry of Health, Turkey
Phase
Phase 3
Overall status
Unknown status
Start date
May 8, 2020
Completion date
June 1, 2021
Enrollment
1,008 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2